XML 21 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue

6.

Revenue

 

The Company’s product revenues were mainly generated from the sale of ETUARY. Sales of ETUARY accounted for 98.4% and 99.2% of total revenue for the three months ended March 31, 2025 and 2024, respectively.

 

Sales of Pharmaceutical Products

The Company generates revenue mostly through sales of ETUARY and certain generic drugs. The distributors are the Company’s direct customers, and sales to distributors account for 100.0% of revenue from ETUARY. The distributors sell ETUARY to outlets, including hospitals and other medical institutions, as well as pharmacies.

Product returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company’s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the product. Revenue from sales of pharmaceutical products was $22.1 million and $27.2 million for the three months ended March 31, 2025 and 2024, respectively. All sales are generated in the PRC. Contract liabilities recognized for the three months ended March 31, 2025 were immaterial.